^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TG4050

i
Other names: TG4050, TG-4050, TG 4050
Associations
Trials
Company:
NEC Corp, Transgene
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
9ms
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 (Yahoo Finance)
"Transgene..., NEC Corporation...and BostonGene Corporation...announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers. BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services. The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture."
Licensing / partnership
|
TG4050
over4years
[VIRTUAL] Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine (AACR-II 2020)
In a similar setting, the netMHC 4.0 algorithm yielded a TP of 30% and only identified 39% of positive calls of our algorithm.We demonstrate that the prediction algorithm is accurate in identifying immunogenic cancer mutations even among a large set of candidates. Ongoing TG4050 clinical studies (NCT03839524 and NCT04183166) will allow further validation of the antitumor activity of the elicited immune response.
Clinical
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
TG4050